机构:[1]Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[2]Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[4]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院
Cancer stem cells (CSCs) are characterized by intrinsic self-renewal and tumorigenic properties, and play important roles in tumor initiation, progression, and resistance to diverse forms of anticancer therapy. Accordingly, targeting signaling pathways that are critical for CSC maintenance and biofunctions, including the Wnt, Notch, Hippo, and Hedgehog signaling cascades, remains a promising therapeutic strategy in multiple cancer types. Furthermore, advances in various cancer omics approaches have largely increased our knowledge of the molecular basis of CSCs, and provided numerous novel targets for anticancer therapy. However, the majority of recently identified targets remain 'undruggable' through small-molecule agents, whereas the implications of exogenous RNA interference (RNAi, including siRNA and miRNA) may make it possible to translate our knowledge into therapeutics in a timely manner. With the recent advances of nanomedicine, in vivo delivery of RNAi using elaborate nanoparticles can potently overcome the intrinsic limitations of RNAi alone, as it is rapidly degraded and has unpredictable off-target side effects. Herein, we present an update on the development of RNAi-delivering nanoplatforms in CSC-targeted anticancer therapy and discuss their potential implications in clinical trials.
基金:
National Natural Science Foundation of China (82073246 and
82003113), China Postdoctoral Science Foundation (220M673208), Post-Doctor Research Project, West
China Hospital, Sichuan University (2020HXBH039 and 2020HXBH061), The Fundamental Research
Funds for the Central Universities (2020SCU12025), 1.3.5 Project for disciplines of excellence,West
China Hospital, Sichuan University (2016105 and ZYGD20006) and Sichuan Science and Technology
Program (2020YFS0068).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|3 区医学
小类|2 区药学
最新[2023]版:
大类|3 区医学
小类|2 区药学
第一作者:
第一作者机构:[1]Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu 610041, China[2]Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China[3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
共同第一作者:
通讯作者:
通讯机构:[2]Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China[3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714):
Tang Yongquan,Chen Yan,Zhang Zhe,et al.Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.[J].Pharmaceutics.2021,13(12):doi:10.3390/pharmaceutics13122116.
APA:
Tang Yongquan,Chen Yan,Zhang Zhe,Tang Bo,Zhou Zongguang&Chen Haining.(2021).Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective..Pharmaceutics,13,(12)
MLA:
Tang Yongquan,et al."Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.".Pharmaceutics 13..12(2021)